tert-butyl 4-(3-chlorophenyl)-4-(1-cyano-2-ethoxy-2-oxoethyl)piperidine-1-carboxylate | 644982-76-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: tert-butyl 4-(3-chlorophenyl)-4-(1-cyano-2-ethoxy-2-oxoethyl)piperidine-1-carboxylate
• 英文别名: 1,1-dimethylethyl 4-(3-chlorophenyl)-4-[1-cyano-2-(ethyloxy)-2-oxoethyl]-1-piperidinecarboxylate
• CAS: 644982-76-3
• 化学式: C₂₁H₂₇ClN₂O₄
• 分子量: 406.909
• InChiKey: JGFRRXXVAJMNFF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  28
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  79.6
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-(3-chlorophenyl)-4-(1-cyano-2-ethoxy-2-oxoethyl)piperidine-1-carboxylate 在 copper(I) oxide 、 sodium hydroxide 、 二异丁基氢化铝 作用下， 以 乙醇 、 二氯甲烷 、 水 、 乙腈 为溶剂， 反应 8.0h， 生成 tert-butyl 4-(3-chlorophenyl)-4-(2-oxoethyl)piperidine-1-carboxylate
  参考文献：
  名称：

  通过温和且可扩展的两步 Cu2O 介导的氰酯脱羧合成 4-取代哌啶

  摘要：

  摘要 报道了制备醛 5 的四步、高产、公斤级方案。关键反应是温和的、两步 Cu2O 介导的氰基酯 3 脱羧反应，该反应以优异的产率进行。还探讨了这种方法的普遍适用性。

  DOI：

  10.1080/00397910500374971
• 作为产物：
  描述：

  氰乙酸乙酯 在 ammonium acetate 、 magnesium 、 溶剂黄146 作用下， 以 乙醚 、 苯 为溶剂， 反应 5.0h， 生成 tert-butyl 4-(3-chlorophenyl)-4-(1-cyano-2-ethoxy-2-oxoethyl)piperidine-1-carboxylate
  参考文献：
  名称：

  Novel 4,4-Disubstituted Piperidine-Based C–C Chemokine Receptor-5 Inhibitors with High Potency against Human Immunodeficiency Virus-1 and an Improved human Ether-a-go-go Related Gene (hERG) Profile

  摘要：

  We recently described (J. Med. Chem. 2008, 51, 6538-6546) a novel class of CCR5 antagonists with strong anti-HIV potency. Herein, we detail SAR converting leads 1 and 2 to druglike molecules. The pivotal structural motif enabling this transition was the secondary sulfonamide substituent. Further fine-tuning of the substituent pattern in the sulfonamide paved the way to enhancing potency and bioavailability and minimizing hERG inhibition, resulting in discovery of clinical compound 122 (GSK163929).

  DOI：

  10.1021/jm200279v

文献信息

• Synthesis of 4‐Substituted Piperidines via a Mild and Scalable Two‐Step Cu₂O‐Mediated Decarboxylation of Cyanoesters
  作者：Brian A. Chauder、Eric E. Boros、Kien S. Du、Wieslaw M. Kazmierski、Cecilia S. Koble、James B. Thompson、Elie A. Tabet

  DOI：10.1080/00397910500374971

  日期：2006.1

  Abstract A four‐step, high‐yielding, kilogram‐scale protocol to prepare aldehyde 5 is reported. The key reaction is a mild, two‐step Cu2O‐mediated decarboxylation of cyanoester 3 that proceeds in excellent yield. The general applicability of this methodology has also been explored.

  摘要 报道了制备醛 5 的四步、高产、公斤级方案。关键反应是温和的、两步 Cu2O 介导的氰基酯 3 脱羧反应，该反应以优异的产率进行。还探讨了这种方法的普遍适用性。
• Chemical compounds
  申请人：Alvaro Giuseppe

  公开号：US20060128752A1

  公开（公告）日：2006-06-15

  The present invention relates to cyclic amine derivatives of formula(l) wherein R represents halogen, C 1-4 alkyl, cyano, C 1-4 alkoxy, trifluoromethyl or trifluoromethoxy; R 1 represents hydrogen, halogen, C 3-7 cycloalkyl, hydroxy, nitro, cyano or C 1-4 alkyl optionally substituted by halogen, cyano or C 1-4 alkoxy; R 2 represents hydrogen or C 1-4 alkyl; R 3 and R 4 independently represent hydrogen, cyano, C 1-4 alkyl or R 3 together with R 4 represents C 3-7 cycloalkyl; R 5 represents trifluoromethyl, S(O) t C 1-4 alkyl, C 1-4 alkyl, C 1-4 alkoxy, trifluoromethoxy, halogen or cyano; R 6 represents hydrogen or (CH 2 )rR 7 ; R 7 represents hydrogen, C 3 7 cycloalkyl, NH(C 1-4 alkylOC 1-4 alkoxy), NH(C 1-4 alkyl), N(C 1-4 alkyl) 2 , OC(O)NR 9 R 8 , NR 8 C(O)R 9 or C(O)NR 9 R 8 ; R 9 and R 8 independently represent hydrogen, C 1-4 alkyl or C 3-7 cycloalkyl; m represents zero or an integer from 1 to 4; n represents 1 or 2; p is zero or an integer from 1 to 3; q is an integer from 1 to 3; r is an integer from 1 to 4; t is 0, 1 or 2; provided that when m is 0, p is 2, q , r and n represent 1, R 1 , R 2 ,R 3 , R 4 , R 5 and R 7 are hydrogen and R is chlorine, R 5 is not iodine; and pharmaceutically acceptable salts and solvates thereof; process for their preparation and their use in the treatment of conditions mediated by tackykinins and/or by selective inhibition of serotonin reuptake transporter protein.

  本发明涉及式（I）的环状胺衍生物，其中R代表卤素、C1-4烷基、氰基、C1-4烷氧基、三氟甲基或三氟甲氧基；R1代表氢、卤素、C3-7环烷基、羟基、硝基、氰基或C1-4烷基，可选地被卤素、氰基或C1-4烷氧基取代；R2代表氢或C1-4烷基；R3和R4独立地代表氢、氰基、C1-4烷基或R3和R4一起代表C3-7环烷基；R5代表三氟甲基、S（O）tC1-4烷基、C1-4烷基、C1-4烷氧基、三氟甲氧基、卤素或氰基；R6代表氢或（CH2）rR7；R7代表氢、C37环烷基、NH（C1-4烷基OC1-4烷氧基）、NH（C1-4烷基）、N（C1-4烷基）2、OC（O）NR9R8、NR8C（O）R9或C（O）NR9R8；R9和R8独立地代表氢、C1-4烷基或C3-7环烷基；m代表零或1至4的整数；n代表1或2；p为零或1至3的整数；q为1至3的整数；r为1至4的整数；t为0、1或2；但当m为0，p为2，q、r和n均为1，R1、R2、R3、R4、R5和R7均为氢，R为氯时，R5不为碘；以及其药学上可接受的盐和溶剂化合物；其制备方法和在治疗由粘附素介导和/或选择性抑制血清素再摄取转运蛋白介导的疾病中的应用。
• Ccr5 antagonists as therapeutic agents
  申请人：Kazmierski Mieczyslaw Wieslaw

  公开号：US20060229336A1

  公开（公告）日：2006-10-12

  The present invention relates to compounds of formula (I) or a pharmaceutically acceptable derivatives thereof, useful in the treatment of prophylazis of CCR5-related diseases and disorders, for example, in the inhibition of HIV replication, the prevention or treatment of HIV infection, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS).

  本发明涉及式(I)化合物或其药学上可接受的衍生物，用于预防CCR5相关疾病和障碍的治疗，例如，抑制HIV复制，预防或治疗HIV感染，以及治疗由此产生的获得性免疫缺陷综合症（AIDS）。
• CCR5 antagonists as therapeutic agents
  申请人：SmithKline Beecham Corp.

  公开号：US07645771B2

  公开（公告）日：2010-01-12

  The present invention relates to compounds of formula (I) or a pharmaceutically acceptable derivatives thereof, useful in the treatment of prophylazis of CCR5-related diseases and disorders, for example, in the inhibition of HIV replication, the prevention or treatment of HIV infection, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS).

  本发明涉及式(I)化合物或其药学上可接受的衍生物，用于预防CCR5相关疾病和障碍的治疗，例如，在抑制HIV复制，预防或治疗HIV感染以及治疗由此引起的获得性免疫缺陷综合症（AIDS）方面。
• [EN] SUBSTITUTED 4-PHENYL-PIPERIDIN-AMIDES AS TACHYKININ ANTAGONISTS AND SEROTONIN REPTAKE INHIBITORS<br/>[FR] COMPOSÉS CHIMIQUES
  申请人：GLAXO GROUP LTD

  公开号：WO2004005256A3

  公开（公告）日：2004-10-14